drugset
Drugs / Allogeneic HB-adMSCs
last change Feb 2026 re-read 3 minutes ago

Allogeneic HB-adMSCs

Cell therapy

Developed for
acute kidney injury
Investigated by
Hope Biosciences LLC · The University of Texas Health Science Center, Houston · University of Alabama at Birmingham · University of California, San Francisco

Trials 1

today NCT06654193 · Ph 1/2
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06654193 Feb 2026 → Jan 2028 expected acute kidney injury Hope Biosciences LLC Recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Allogeneic HB-adMSCs ClinicalTrials.gov intervention name — accepted as the source's own label NCT06654193 ↗
Modality Cell therapy “Allogeneic Adipose-derived Mesenchymal Stem Cells (MSC)” NCT06654193 ↗